VALBIOTIS SA: Valbiotis announces the success of its capital increase of €10.2M
|
VALBIOTIS SA Press release
Valbiotis announces the success of its capital increase of €10.2M, fully dedicated to supporting the commercial expansion of its range of scientifically tested natural healthcare products to prevent cardiometabolic imbalances
La Rochelle, June 26, 2026 (6:00 PM CET) – Valbiotis (FR0013254851 – ALVAL, PEA/PME eligible), a French laboratory specializing in the design and distribution of scientifically tested natural healthcare products to prevent cardiometabolic imbalances and address everyday health issues, announces the success of its capital increase with shareholders’ pre-emptive subscription rights maintained. This fundraising of €10.2M is intended to finance the acceleration of the Company’s commercial development in France and internationally and support self-financed growth. Sébastien Peltier, Chairman of the Board of Directors and Co-Founder of Valbiotis , comments: “This successful fundraising further strengthens Valbiotis ’ rapid growth trajectory as we expand our commercial network and secure supply for our markets in France, Asia and the Middle East. I sincerely thank all the investors whose strong mobilization made this transaction possible: the institutional investors who secured it upstream; Xianhua Tao, whose personal participation further strengthens the strategic ties between Aika and Valbiotis ; and our individual shareholders, whose loyalty and trust we are committed to honoring. We approach this acceleration phase with confidence and the conviction that Valbiotis has all the strengths needed to become a reference player in scientifically tested natural healthcare products.” OFFERING RESULTS At the end of the subscription period, total demand on an irreducible, reducible and unrestricted basis amounted to 7,204,512 new shares subscribed at a unit price of €0.86, representing 60.85% of the maximum number of new shares to be subscribed, which was 11,840,000. Total demand breaks down as follows:
These subscription requests on an irreducible, reducible and unrestricted basis were satisfied in full. It should be noted that the Company had received a subscription commitment for a total amount of €2.0M from Ximen RD PTE Ltd, a company wholly owned by Xianhua Tao and a 51% shareholder alongside Valbiotis in the China-based joint venture. As subscription requests on an irreducible, reducible and unrestricted basis represented approximately 60.8% of the amount of the issue, that is, €6.2M, a total of 4,635,488 new shares, representing 39.2% of the amount of the issue, were allocated and attributed to the shareholders and investors who had committed to subscribe under the issue guarantee, together the “Guarantors”. These guarantee commitments could be called upon if the number of new shares subscribed at the end of a subscription period does not reach 100% of the maximum amount of the capital increase. As indicated in the press release announcing the launch of the capital increase, the 4,635,488 new shares allocated to the Guarantors, representing approximately €4.0M and corresponding to an allocation rate of 74.6% of the commitments received from the Guarantors, were distributed among them on a pro rata basis. Out of the €5,797K in guarantee commitments received by the Company, the final allocations to the Guarantors are as follows, it being specified that the commitment made by Avenir France PME, managed by Talence Patrival, to subscribe under the guarantee for €450K is included in the amount of subscriptions on a reducible basis:
As a result, the total number of shares allocated under the capital increase is 11,840,000 and the allocation summary is as follows:
(1) Including €450K in respect of the subscription guarantee commitment given by Avenir France, managed by Talence Patrival REMINDER OF THE USE OF THE OFFERING PROCEEDS The net proceeds of the issue will amount to approximately €8.9 M and will support the Company’s commercial expansion. The funds raised will be allocated to the following objectives:
Given the cash position available at the end of April 2026, the expected acceleration of business in line with the strategic plan already communicated and the financial debt repayment schedule, the Company believes that the net proceeds of the Offering, namely €8.9 M, will provide a cash runway extending beyond the third quarter of 2027, not including any potential non-dilutive financing sources that remain to be determined and negotiated, with the Company maintaining its objective of positive EBITDA for fiscal year 2027
SETTLEMENT-DELIVERY
Settlement-delivery and admission of the new shares to trading on the Euronext Growth Paris market are scheduled for June 30, 2026. The new shares will carry current dividend rights, will be immediately assimilated with the Company’s existing shares and will be traded on the same listing line as those shares under the same ISIN code (FR0013254851 – Ticker: ALVAL).
Following settlement-delivery, the Company’s share capital will amount to €3,553,823.40 and will be divided into 35,538,234 ordinary shares with a par value of €0.10 each.
IMPACT OF THE TRANSACTION ON THE SHAREHOLDING STRUCTURE To the Company’s knowledge, the breakdown of share capital and voting rights before and after completion of the capital increase is as follows.
Impact of the Offering on the breakdown of share capital
Impact of the Offering on the breakdown of voting rights
IMPACT OF THE OFFERING ON CONSOLIDATED EQUITY PER SHARE
and BSPCEs, which could result in the issuance of a total of 1,439,856 shares.
IMPACT OF THE OFFERING ON THE POSITION OF A SHAREHOLDER HOLDING 1% OF THE SHARE CAPITAL AND NOT SUBSCRIBING TO THE OFFERING
LOCK-UP AND HOLDING COMMITMENTS Sébastien Peltier, Chairman of the Board of Directors, has undertaken to retain the shares he will hold through his holding company Djanka Investissement following this issuance for a period of 180 days after the settlement-delivery date of the capital increase. In addition, the Company has undertaken a 180-day standstill commitment following the settlement-delivery date of the capital increase, subject to customary exceptions. PROSPECTUS The transaction does not require a prospectus subject to AMF approval, as the total amount of the offering calculated over a twelve-month period does not exceed €12M.
RISK FACTORS The Company notes that the risk factors relating to the Company and its business are detailed in the Universal Registration Document for fiscal year 2025 (Chapter 3), available on the Company’s website (www.valbiotis.com) under the Investors / Regulated Information section (Registration Document). The occurrence of all or part of these risks could have an adverse effect on the Company’s business, financial position, results, development or outlook. The risk factors presented in the above-mentioned document remain unchanged as of the date of this press release.
SHARE INFORMATION
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. These statements do not constitute historical facts. These statements include projections and estimates, as well as the assumptions on which they are based, including statements relating, in particular, to plans, objectives, intentions and expectations regarding financial results, product potential or future performance. These forward-looking statements can often be identified by the words “expect”, “anticipate”, “believe”, “intend”, “estimate” or “plan”, as well as by other similar terms. Although VALBIOTIS’ management believes that these forward-looking statements are reasonable, investors are advised that they are subject to numerous risks and uncertainties, which are difficult to predict and generally beyond VALBIOTIS’ control, and which could cause actual results and events to differ materially from those expressed, implied or forecast in the forward-looking information and statements. These risks and uncertainties include, in particular, those developed or identified in the Universal Registration Document for fiscal year 2025 (Chapter 3), available on the Company’s website (www.valbiotis.com) under the Investors / Regulated Information section. Valbiotis undertakes no obligation to update any forward-looking information or statements, subject to applicable regulations, in particular Articles 223-1 et seq. of the General Regulation of the French Financial Markets Authority.
WARNING
This press release does not constitute an offer to sell or a solicitation of an offer to buy, and no sale of common shares will take place in any state or jurisdiction in which such offer, solicitation or sale would be unlawful without registration or approval under the securities laws of such state or jurisdiction.
The distribution of this press release may be subject to specific regulations in certain countries. Persons in possession of this document are required to inform themselves of any such local restrictions and to comply with them.
This press release constitutes a promotional communication and not a prospectus within the meaning of Regulation (EU) 2017/1129 of the European Parliament and of the Council of June 14, 2017, as amended (the Prospectus Regulation).
With respect to Member States of the European Economic Area other than France (the Member States), no action has been taken or will be taken to permit a public offering of the securities requiring the publication of a prospectus in any such Member State. Accordingly, the securities may not be offered and will not be offered in any Member State (other than France), except in accordance with the exemptions provided for in Article 1(4) of the Prospectus Regulation, or in other cases not requiring the publication by Valbiotis of a prospectus under the Prospectus Regulation and/or the regulations applicable in such Member States. This press release does not constitute a public offering of securities in the United Kingdom.
This press release may not be published, distributed or released in the United States (including its territories and possessions). This press release does not constitute an offer or a solicitation to buy, sell or subscribe securities in the United States. The financial securities referred to in this press release have not been registered under the U.S. Securities Act of 1933, as amended (the Securities Act), or under any applicable securities regulations of any state or other jurisdiction in the United States and may not be offered or sold in the United States absent registration under the Securities Act except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act. Valbiotis does not intend to register the offering in whole or in part in the United States under and in accordance with the Securities Act, or to conduct a public offering in the United States. This press release may not be distributed, directly or indirectly, in the United States, Canada, Australia or Japan. Lastly, this press release may be prepared in both French and English. In the event of any differences between the two texts, the French version shall prevail.
TRANSACTION PARTNERS
About Valbiotis
Valbiotis is a French laboratory specializing in the development and distribution of scientifically tested first-line nutritional solutions designed to prevent cardiometabolic imbalances. Through an innovative approach combining scientific excellence, plant expertise and a wealth of natural ingredients, Valbiotis develops high-quality formulations based on patented active ingredients validated by rigorous clinical studies, designed to provide long-term support for cardiometabolic health and address associated functional issues such as sleep, fatigue, mood management, immunity and vitality. Created at the beginning of 2014 in La Rochelle, France, Valbiotis has forged numerous partnerships with leading academic centers. Valbiotis is a member of the “BPI Excellence” network and has been recognized as an “Innovative Company” by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-PME eligible company. For more information on Valbiotis ®, please visit: www.valbiotis.com
Contacts Corporate Communications / Valbiotis Caroline Lamberti +33 6 77 82 56 88 caroline.lamberti@valbiotis.com
Financial Communications / Seitosei-Actifin Marianne Py +33 6 85 52 76 93 marianne.py@seitosei-actifin.com
Press Relations / Seitosei-Actifin Enora Budet +33 6 72 17 84 60 enora.budet@seitosei-actifin.com
Regulatory filing PDF file File: CP_résultat_final_Vdef_EN 02 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Language: | English |
| Company: | VALBIOTIS SA |
| 12F, Rue Paul Vatine | |
| 17180 Périgny | |
| France | |
| Phone: | 0546286258 |
| E-mail: | contact@valbiotis.com |
| Internet: | www.valbiotis.com |
| ISIN: | FR0013254851 |
| Euronext Ticker: | ALVAL |
| AMF Category: | Inside information / Issuer activities (acquisitions, sales...) |
| EQS News ID: | 2355154 |
| End of Announcement | EQS News Service |
2355154 26-Jun-2026 CET/CEST
| About us | Network | Partners |
| Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos |
Analist.nlLinksISIN
|
MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-x |
